ProCE Banner Activity

Omicron Subvariant Therapeutic Updates

Multimedia
Hear expert insights on ivermectin as a treatment for COVID-19 and evolving information on monoclonal antibodies during the latest omicron wave.

Released: June 07, 2022

Expiration: June 06, 2023

Share

Faculty

Sharon R. Lewin

Sharon R. Lewin, AO, FRACP, PhD, FAHMS

Director, The Peter Doherty Institute for Infection and Immunity
Professor of Infectious Diseases
University of Melbourne
Consultant Infectious Diseases Physician
Alfred Hospital and Royal Melbourne Hospital
Melbourne, Australia

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp

Faculty Disclosure

Primary Author

Sharon R. Lewin, AO, FRACP, PhD, FAHMS

Director, The Peter Doherty Institute for Infection and Immunity
Professor of Infectious Diseases
University of Melbourne
Consultant Infectious Diseases Physician
Alfred Hospital and Royal Melbourne Hospital
Melbourne, Australia

Sharon R. Lewin, AO, FRACP, PhD, FAHMS, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and ViiV Healthcare; funds for research support from Leidos; and other financial or material support from Gilead Sciences, Merck, and ViiV Healthcare.